All In Biotech

NDA 018248 · Fresenius Kabi USA

Oxytocin

Oxytocin · Injection · Oxytocic

Last checked: Nov 19, 2026Latest source record: Sep 20, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1980

Jul 9, 1980

Approved uses

1

Original approval plus efficacy supplements

Registered trials

722

71 Phase 3, 51 recruiting

FAERS reports

2,568

2,294 serious, 145 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 12, 2026.

INDICATIONS AND USAGE IMPORTANT NOTICE: Oxytocin Injection, USP (synthetic) is indicated for the medical rather than the elective induction of labor. Available data and information are inadequate to define the benefits to risks considerations in the use of the drug product for elective induction. Elective induction of labor is defined as the initiation of labor for convenience in an individual with a term pregnancy who is free of medical indications. Antepartum Oxytocin injection (synthetic) is indicated for the initiation or improvement of uterine contractions, where this is desirable and considered suitable, in order to achieve early vaginal delivery for fetal or maternal reasons. It is indicated for (1) induction of labor in patients with a medical indication for the initiation of labor, such as Rh problems, maternal diabetes, pre-eclampsia at or near term, when delivery is in the best interest of mother and fetus or when membranes are prematurely ruptured and delivery is indicated; (2) stimulation or reinforcement of labor, as in selected cases of uterine inertia; (3) adjunctive therapy in the management of incomplete or inevitable abortion. In the first trimester, curettage is generally considered primary therapy. In second trimester abortion, oxytocin infusion will often be successful in emptying the uterus. Other means of therapy, however, may be required in such cases. Postpartum Oxytocin injection (synthetic) is indicated to produce uterine contractions during the third stage of labor and to control postpartum bleeding or hemorrhage. Antepartum Oxytocin injection (synthetic) is indicated for the initiation or improvement of uterine contractions, where this is desirable and considered suitable, in order to achieve early vaginal delivery for fetal or maternal...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 9, 1980 Original approval · Type 5 - New Formulation or New Manufacturer
3 products under this application
  • OXYTOCIN · OXYTOCIN 100USP UNITS/10ML (10USP UNITS/ML) · INJECTABLE, INJECTION · Prescription · TE AP
  • OXYTOCIN · OXYTOCIN 300USP UNITS/30ML (10USP UNITS/ML) · INJECTABLE, INJECTION · Prescription
  • OXYTOCIN · OXYTOCIN 10USP UNITS/ML (10USP UNITS/ML) · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Oxytocin" as an intervention, any sponsor and status, largest first.

All 722 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • foetal exposure during pregnancy413
  • maternal exposure during pregnancy398
  • drug ineffective353
  • exposure during pregnancy317
  • premature baby197
  • off label use163
  • hypotension160
  • premature delivery156
  • maternal exposure during delivery112
  • low birth weight baby101
  • drug exposure during pregnancy99
  • postpartum haemorrhage98

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200434
200522
200654
200732
200851
200940
201053
201151
201250
201371
201487
201589
2016151
2017124
2018158
2019137
2020193
2021188
2022228
2023266
2024186
2025161
2026140

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3,034 on PubMed

Sponsor: Fresenius Kabi USA

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.